Akers Biosciences Completes Study on First Rapid Breath Test for Oxidative Stress
August 18 2016 - 7:00AM
Marketwired
Akers Biosciences Completes Study on First Rapid Breath Test for
Oxidative Stress
Test Demonstrates 99.5% Correlation With Reference Laboratory
Method
THOROFARE, NJ-(Marketwired - Aug 18, 2016) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company" or "Akers Bio"), a
developer of rapid health information technologies, announces the
results of a study of the Company's BreathScan OxiCheck test
("OxiChek"), the first disposable breath test to rapidly determine
levels of oxidative stress in the body - an indicator of the
overall health and wellbeing of a person.
The study was performed in Philadelphia, PA, under the
supervision of Adam C. Sobel M.D., Director, Medical of Akers Bio.
The results were highly successful with a correlation between
OxiChek and the standard reference laboratory blood testing method
(TBARS) of 99.5%. The study demonstrated a reproducibility of 100%,
meaning the test results from the same lung simulator had zero
variation after multiple repeats. The study further demonstrated an
intra-subject variation ranging from 1.61% to 14.87%, indicating a
narrow variation upon multiple repeat tests by the same human
subject.
OxiChek is a general wellness product from Akers Wellness,
intended to measure indicators of oxidative stress in exhaled
breath. Unlike current laboratory testing methods that test only a
few free radicals using an invasive blood draw - and have a
turnaround time of 7 to 10 days - Akers Bio's rapid OxiChek test
detects a broad spectrum of free radicals contained in a person's
exhaled breath in just a few minutes.
OxiChek works with BreathScan Lync, the new bluetooth-enabled
reading device from Akers Wellness, to enable users to track their
results via a mobile device. It can be used to promote, track
and/or encourage choices, such as use of nutritional supplements
which, as part of a healthy lifestyle, may help to reduce the risk
of certain chronic diseases or conditions.
Raymond F. Akers, Jr. PhD, Co-founder and Chief Scientific
Director of Akers Bio, said: "Once again a study has demonstrated
an exceptionally high correlation between an Akers Bio rapid breath
test and an established reference laboratory blood test. This
further underpins the value which we believe lies within our
proprietary breath testing technology which we have always believed
would very closely mirror blood testing for certain biomarkers.
"We are very excited about these particular study results for
OxiChek. Not only do they demonstrate the effectiveness of our test
for oxidative stress, but the comparison to the standard reference
laboratory test - blood vs breath - is remarkable. Add to this the
results of an earlier study that showed a significant correlation
between OxiChek results and the age of the test subjects, and we
believe that we have a powerful tool for the expansive health and
wellness and anti-aging industry."
John J. Gormally, Chief Executive Officer of Akers Bio, added:
"I am delighted with the outcome of this study. Our work in
demonstrating the efficacy of the OxiChek test strongly underpins
the commercialization strategy for this exciting new product from
Akers Bio. We have just begun selling OxiChek through our recently
appointed distributor Aero-Med, which is targeting the anti-aging,
functional and integrative health and wellness treatment
practitioner market in the US; and we are also in active
discussions with other distribution partners for OxiChek with
capabilities within other target markets."
BreathScan OxiChek and other Akers Bio health and wellness tests
do not require US FDA clearance and are being marketed now in the
US and other territories covered by the Company's international
distribution network.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target," "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information: Akers Biosciences, Inc. Raymond F. Akers,
Jr. PhD Co-founder and Chief Scientific Director Tel. +1 856 848
8698 Taglich Brothers, Inc. (Investor Relations) Chris Schreiber
Tel. +1 917 445 6207 Email: cs@taglichbrothers.com finnCap (UK
Nominated Adviser and Broker) Adrian Hargrave / Scott Mathieson
(Corporate Finance) Steve Norcross (Broking) Tel. +44 (0)20 7220
0500 Vigo Communications (Global Public Relations) Ben Simons /
Fiona Henson Tel. +44 (0)20 7830 9700 Email:
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024